NCT03551782 2022-02-25A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate CancerJanssen Research & Development, LLCPhase 1 Completed33 enrolled